Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...

Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in ...

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) e estimate Rivian’s stock price to be $140.00 per share. Our estimated stock ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...